CDI-988 Safety Study in Healthy Participants

The goal of this clinical trial is to learn about the safety and pharmacokinetics (PK, the amount of drug in the blood) of a new drug called CDI-988 in healthy volunteers. The main questions it aims to answer are: * Are there any side effects of the drug? * What is the amount of drug that reaches the bloodstream? Participants will be assigned by chance to take either CDI-988 or placebo by mouth and have physical exams, electrocardiograms (ECGs), vital signs, and blood tests to look for any side effects.

Inclusion Criteria: * Healthy males or non-pregnant, non-lactating females * Body weight of at least 45 kg. * Body mass index ≥18.0 and ≤32.0 kg/m2 * Good state of mental and physical health * Negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test Exclusion Criteria: * Received an investigational drug within 30 days * Received a coronavirus disease 2019 (COVID-19) vaccine within 7 days * Drug or alcohol abuse in the past 12 months * Clinically significant abnormal biochemistry, hematology, coagulation, urinalysis test results * Clinically significant abnormal ECG or vital signs